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Abstract
Heart disease is the leading cause of death in the US. Following an acute myocardial infarction, a
fibrous, noncontractile scar develops, and results in congestive heart failure in more than 500,000
patients in the US each year. Muscle regeneration and the induction of new vascular growth to treat
ischemic disorders of the heart can have significant therapeutic implications. Early studies in patients
with chronic ischemic SLVD using skeletal myoblasts or bone marrow-derived cells report
improvement in left ventricular ejection function (LVEF) and clinical status, without notable safety
issues. Nonetheless, the efficacy of cell transfer for cardiovascular disease is not established, in part
due to a lack of control over cell retention, survival, and function following delivery. We studied the
use of biocompatible hydrogels polymerizable in situ as a cell delivery vehicle, to improve cell
retention, survival, and function following delivery into the ischemic myocardium. The study was
conducted using human bone marrow-derived mesenchymal stem cells and fibrin glue, but the
methods are applicable to any human stem cells (adult or embryonic) and a wide range of hydrogels.
We first evaluated the utility of several commercially available percutaneous catheters for delivery
of viscous cell/hydrogel suspensions. Next we characterized the polymerization kinetics of fibrin
glue solutions to define the ranges of concentrations compatible with catheter delivery. We then
demonstrate the in vivo effectiveness of this preparation and its ability to increase cell retention and
survival in a nude rat model of myocardial infarction.
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INTRODUCTION
Congestive heart failure (CHF) is an enormous health problem in the US, affecting nearly 5
million people (0.5 million newly diagnosed/year) and imposing a significant burden on those
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afflicted (12–15 million office visits, 6.5 million hospital days, and almost 0.3 million deaths/
year) that is surely to increase as the population ages (7). While cardiac transplantation remains
the definitive treatment for end-stage heart failure, it is seriously limited by a scarcity of
available donor organs. Alternative approaches such as cell-based therapies have therefore
garnered much attention in recent years. Early cell therapy studies utilized skeletal myoblasts
(12) or bone marrow-derived stem cells (11) with or without concomitant revascularization.
These studies demonstrated modest gains in left ventricular ejection fraction (LVEF) and
clinical status, along with excellent safety profiles of cell injection techniques (15). However,
the efficacy of cell-based procedures has not been well established, in part due to a lack of
control over cell retention, survival, and function following delivery.
The key limitation of all existing modalities of cell delivery is the massive cell loss that occurs
within a very short time and, irrespective of cell type or formulation, delivery technique and
disease state. Estimates for acute retention vary depending upon route of delivery but are
uniformly poor (5,9). For instance, in an elegant study utilizing radio-labeled bone marrow
mononuclear cells (6), only 11 ± 3% of cells remained in the heart just 90 min after
intramyocardial injection. Retention rates for intracoronary (2.6 ± 0.3%) and retrograde venous
delivery (3.2 ± 1.0%) were even lower. All three methods were associated with rapid
redistribution of the cells delivered into the heart to the lungs, liver, spleen, and other organs
throughout the body. Postulated mechanisms for poor retention include inadvertent
intravascular delivery to coronary veins and venules, rapid interstitial clearance by lymphatics,
and direct leakage of cell suspension once the needle is removed.
In addition, the local environment presents an untenable milieu for freshly implanted cells
following both acute (inflammation) and chronic (fibrosis) myocardial infarction (14). The
infarct bed is poorly oxygenated, contains dead and apoptotic cells, and has a progressively
increasing stiffness, a combination of features that does not support the viability and well-being
of implanted cells. This additional limitation of delivering “naked” cells has prompted research
towards multiple other modalities for cell delivery—from the use of biomaterials as cell
delivery vehicles (4) to engineering a contractile cardiac “patch” containing the repair cells
(10).
Intramyocardial in situ polymerization of polymers in form of a hydrogel represents one
possible solution to address both leakage and clearance-mediated cell loss, and the need for
“conditioning” of the immediate cell environment. There are a number of biocompatible
hydrogels, polymerizing in response to chemical, thermal, or optical triggers, including fibrin
(1), alginate (8), and polyethylene glycol-based systems (2). Fibrin glue is a hydrogel widely
used in surgery, cell culture, and tissue engineering that consists of a two-component system.
Fibrinogen monomers (component A) are dissolved in a liquid carrier such as saline. Exposure
of fibrinogen monomers to thrombin (component B) results in conversion of fibrinogen to
fibrin, which polymerizes to form a fibrin mesh, by mechanisms similar to those involved in
normal clotting in vivo. Both autologous and recombinant off-the-shelf fibrin glue preparations
are available, and have seen extensive use as procoagulants during cardiac and other surgery.
Additionally, preclinical literature supports an angiogenic role for fibrin glue following
myocardial ischemia in rats, making this an attractive system for possible catheter-based cell
therapy of the heart (3).
Cell delivery to the heart is being performed by surgical and catheter-based (percutanous)
methods. Catheter-based cell delivery has several advantages over direct surgical injection: 1)
lower procedure risk, 2) high potential for integration into clinical practice, and 3) more
suitability for repeat applications compared to surgery. For these reasons, the majority of
current cardiac cell therapy trials employ a percutaneous delivery method, the most common
type of which is endoventricular or transendocardial injection (13).
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However, the use of intramyocardial injection catheters also imposes significant design
constraints on a cell/hydrogel preparation (Fig. 1). First, the long internal lumen of the catheter
imposes a high resistance to flow that in turn limits the maximum viscosity of the injectate.
Second, because current catheters employ a single injection lumen, the fibrin glue components
must be mixed prior to injection, resulting in a time-dependant increase in viscosity of cell/
hydrogel suspension. A successful formulation must therefore polymerize quickly enough to
improve cell retention, yet slowly enough to allow adequate time for injection site selection,
catheter positioning, and delivery.
In this article we first assess the utility of several commercially available percutaneous catheters
using standards of solutions with known viscosity to determine a working limit for this
parameter. Next we characterize the polymerization kinetics of different fibrin glue solutions
to define the ranges of parameters compatible with catheter delivery. We then demonstrate the
in vitro and in vivo effectiveness of this preparation, and its ability to increase cell retention
and prevent redistribution of delivered product in an animal model of myocardial infarction.
MATERIALS AND METHODS
Viscosity Limit of Clinically Available Catheters
A system for rheological measurements with constant fluid pressure was established, whereby
a solution was pushed through each of the catheters tested at a constant flow velocity. Dextran
solutions of known viscosity (Sigma, at 5%, 10%, 20%, 25% w/v) were passed through
catheters and the ease with which the solution flowed was characterized as “easily
delivered” (+), “low flow” (LF), or “no flow” (NF). Viscosities of each dextran solution were
then confirmed using an ARES-LS1 Rheometer (TI Instruments), using cone-and-plate
configuration with diameter of 5 cm, and angular displacement of 0.01 radians at 1 Hz.
Time-Dependent Viscosity Profiles
Bovine fibrinogen (Sigma) was dissolved in PBS to yield 1%, 2%, 5%, 10%, and 15% (w/v)
solutions. Each of these solutions was loaded into the cone-and-plate configured Ares-LS1
Rheometer (TA instruments). Thrombin (Sigma T6200) was reconstituted to a concentration
of 100 U/ml. Diluted thrombin, 50 U/ml and 20 U/ml, was combined with fibrinogen at a
concentration of 2%, 5%, or 10% w/v to initiate polymerization to fibrin glue.
Cell Viability in Fibrin
To obtain human mesenchymal stem cells (hMSCs), human bone marrow mononuclear cells
(LONZA 2M-125) were plated in T75 flasks and cultured in DMEM (Gibco, #12430) with
10% FBS (Gibco, #26140). The adherent cells were expanded to the fourth passage for use in
all subsequent experiments. hMSCs were encapsulated in fibrin gels at a density of 4 × 106
cells/cm3.
Fibrin gels were fabricated by combining 2% w/v fibrinogen with 20 U/ml thrombin in a 96-
well plate. At time points of 0.5, 24, and 72 h after gel fabrication, gels were stained with LIVE/
DEAD Invitrogen L-3224 and digital images obtained from a fluorescent microscope. Images
were then analyzed in Matlab using codes written to allow automated unbiased counting of red
(dead) and green (live) hMSCs.
Scanning Electron Microscopy
Fibrinogen from bovine serum was dissolved to 2% (w/v) solution and polymerized with 50
U/ml thrombin to produce 500 μl volume aliquots of hydrogels. Hydrogels were placed in
sterile water, submerged in liquid nitrogen, freeze-dried using a lyophilizer (Labconco
7740020), and sputtered-coated with 10 nm gold-palladium in a Denton Desktop-2 sputtering
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system. Samples were then mounted onto carbon tape and imaged in Hitachi 4700 Scanning
Electron Microscope at a range of magnifications between 20 and 1000× and digitally stored.
Animal Model and Quantification of Retention
Rowett (rnu/rnu) athymic nude rats (Harlan Sprague-Dawley) were used in studies approved
by the Columbia University Institutional Animal Care and Use Committee (IACUC). Rats
were anesthetized with inhalation of isoflurane (2–3%), endotracheally intubated, and
mechanically ventilated. The heart was exposed through a left thoracotomy and the pericardium
incised. The LAD was then ligated with 7-0 prolene suture 2–3 mm below the edge of the left
atrium. Confluent T75 flasks of fourth passage hMSCs were incubated overnight with 10 μl
of iridium colloid label (Biopal, CL-300G02-1) prior to injection. Aliquots of 500,000 labeled
hMSCs were suspended either in 300 μl of PBS (n = 6) or a 300-μl mixture of fibrin glue (2%
w/v fibrinogen, 20 U/ml thrombin, n = 6) and immediately injected into the border zone in two
divided injections of 150 μl each. Ninety minutes after cell injection, the rats were euthanized
and the heart, lungs, liver, kidneys, and spleen were recovered. Tissue specimens were
dehydrated and sent to Biopal for neutron beam bombardment and quantification according to
the manufacturer's protocol.
Quantitative PCR Analysis
Total RNA was isolated by lysing freshly pelleted cells by an RNAqueous isolation kit
(Ambion #AM1912). DNA contamination was enzymatically removed (Turbo DNAse,
Ambion) and 1 μg of total RNA was used to build a cDNA library with the Reaction Ready
cDNA Synthesis kit (Superarray Bioscience Corporation) and a Biorad MyCycler according
to the manufacturer's specification. Custom RT2Profiler PCR Arrays (Superarray Bioscience
Corporation, cat. #CAPH-0154B) were then run on a Stratagene MX-3005 cycler according
to the manufacturer's protocol and analyzed with MxPro v3.0 software. Fold changes were
expressed using the ΔΔCt method with normalization of the raw data to the GAPDH
housekeeper.
Statistical Analysis
All averages are reported as mean ± SD. For comparison between fibrin and saline suspended
cells, a two-tailed Student's t-test was used with p < 0.05 considered significant.
RESULTS
Given the importance of hydrogel flow properties for catheter-based delivery of cell/hydrogel
suspensions, we first specified the range of hydrogel viscosity that is compatible with the use
of a catheter. Hydrogel preparations were formed by utilizing dextran-based standards, to
obtain a series of solutions with a gradually increasing viscosity. Four different catheter types
with a wide range of path lengths (115–177.5 cm) and inner diameters (0.19–0.43 mm) were
used in these rheological studies. Table 1 summarizes these studies. Dextran solutions with
concentrations less than 5% w/v (viscosity of ≤9.39 cP) were easily passed through all four
catheters. All catheters except for the one with the longest and most narrow lumen (catheter
D) handled the 10% dextran solution (viscosity of 30.8 cP) with ease. Injection of 20% dextran
solutions (viscosity of 121 cP) was possible through catheters A, B, and C, but significantly
more force was required compared to less viscous solutions to produce forward flow. Only the
catheter with the shortest path length (catheter C) was able to pass 25% dextran solutions (231
cP). From these tests we estimated an operational viscosity upper limit in the 150–200 cP range.
Next we analyzed the starting viscosity of fibrinogen suspended in saline prior to addition of
thrombin and initiation of polymerization (Fig. 2a). Fibrinogen solutions demonstrated a
nonlinear increase in viscosity; however, all solutions tested were well under the established
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upper limit of 200 cP. Above fibrinogen concentrations of 15%, visible clumping occurred and
could only be overcome by elevating the temperature of the mixture well above body
temperature. Having now established acceptable starting concentrations of fibrinogen (<15%
w/v) we characterized the time-dependent changes in viscosity associated with addition of
thrombin and polymerization of fibrin monomers (Fig. 2b). Early testing with higher fibrinogen
concentrations (>10% w/v) was associated with rapid polymerization that was incompatible
with percutaneous delivery. In contrast, by decreasing the starting concentrations of fibrinogen
to 5% and of thrombin to 20 U/ml, injection windows in the 6–8 min range could be achieved.
Of note, fibrin glue preps crossing the 200 cP limit could be easily cleared from catheter C by
manual flushing with saline, enabling reuse of the catheter with freshly mixed fibrin glue.
To characterize the biocompatibility of fibrin glue, we encapsulated fourth passage
mesenchymal stem cells in 2% w/v gels polymerized with 20 U/ml of thrombin. This
preparation demonstrated excellent long-term viability (Fig. 3a) and normal morphology (Fig.
3b) over 72 h of culture with hMSCs maintaining >90% viability at all time points. After 72
h, hydrogels were lyophilized for scanning electron microscopy (SEM), which demonstrated
pore sizes in the 20–40 mm range (Fig. 3c) and a somewhat homogenous architecture (Fig.
3d). RT-PCR analysis of several hMSC markers including α-smooth muscle actin and
connexin-43 showed no significant change in expression after 72 h of culture in fibrin glue
(data not shown).
Having established acceptable parameters for percutaneous application, we tested the in vivo
effectiveness of intracardiac polymerization of fibrin glue in a rat model of acute myocardial
infarction. Early attempts to inject hydrogel via a 23-gauge needle resulted in excessive
bleeding. After the needle size was reduced to 26 gauge 5/8 in., successful delivery of a 2%
w/v fibrinogen/20 U/ml thrombin preparation was achieved with reproducible results.
Intracardiac injection of this preparation resulted in a visible blanching of the anterior wall
with no appreciable loss of injectate from the injection site (Fig. 4a). Ten days postinjection
the anterior wall demonstrated visible retention of polymerized fibrin grossly (Fig. 4b, c) and
histologically (Fig. 4d).
To quantify the effect of in situ polymerization of fibrin glue on cell retention and redistribution,
we next suspended 500,000 iridium-labeled hMSCs in either saline or fibrin glue (2% w/v
fibrinogen, 20 U/ml thrombin) and delivered them into acutely infarcted nude rats via two
separate 150-μl injections. Ninety minutes after cell delivery, the rats were sacrificed and the
hearts and remote organs procured for quantification of retained cells (Fig. 4e). There was no
significant difference in the total number of hMSCs recovered from the heart and remote organs
(3.31 ± 1.39 × 105 vs. 3.41 ± 1.00 × 105, fibrin glue vs. saline). Delivery of hMSCs in fibrin
glue was associated with a substantial increase in local cardiac retention (39.7 ± 7.0% vs. 22.6
± 3.5% of recovered cells, p < 0.05) as well as a significant reduction in redistribution to the
liver (21.7 ± 7.9% vs. 41.7 ± 0.4%, p < 0.05) and kidney (0.3 ± 0.3% vs. 8.9 ± 8.8%, p < 0.05).
Interestingly, redistribution of hMSCs to the lungs was not statistically different for the two
methods (38.3 ± 14.6% vs. 23.9 ± 9.3%).
DISCUSSION
Heart failure following acute and chronic myocardial infarction remains a therapeutic challenge
with gradual progression of disease and functional decline leading to death being the most
common outcome. Various modalities of cell delivery have gained a lot of attention in recent
years. While early clinical trial results were very promising, larger randomized trials have
produced conflicting data, sometimes with similar cell types showing sometimes positive and
sometimes negative results. This lack of convincing evidence for the efficacy of delivered cells
may due to differences in cell processing, delivery methods, and timing of administration, such
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that poor cell retention and engraftment remain a central problem common to all cell types and
routes of administration.
In this study, we have demonstrated that by controlling the composition of fibrinogen and
thrombin components, a fibrin-based hydrogel can be prepared that is compatible with current
percutaneous injection catheters. This hydrogel can be delivered under clinically relevant
conditions (point of care component mixing, 10-min injection window) and greatly enhances
local retention of injected cells in the heart as well as prevents their redistribution to distance
organs. Furthermore, the system and parameters developed here are applicable to all cell types
and may represent an enabling technology capable of improving current cell delivery
techniques.
While some of the currently available catheters were suitable for cell/hydrogel delivery, a
number of avenues for design improvement exists. First, given that the device with shortest
path length and largest internal luminal diameter performed best, increasing the inner diameter
even slightly may result in broadening the injection window by raising the upper limit of
passable viscosity. Second, a double-lumen system that keeps the fibrinogen and thrombin
components isolated until they reached the target tissue would potentially relieve the timing
constraints associated with intracatheter polymerization altogether.
As this was only an initial pilot study, more robust functional studies should be undertaken to
determine if the retention and distribution benefit demonstrated here results in greater
functional recovery. The technique should also be applied to other cell types to confirm its
broader potential. Alternative hydrogel systems are also available, allowing for the possibility
of matching cell types to hydrogel compositions. Further functionalization of these hydrogels
through growth factor tethering or backbone modification may result in even greater benefit
and should be explored.
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Catheter-based delivery of actively polymerizing compounds is limited by increasing
resistance to flow over time and requires a balance between overly rapid (clogged catheter)
and overly slow (loss of cell product) kinetics.
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(a) Fibrinogen solutions show a nonlinear increase in viscosity with increasing weight
percentage. (b) By maintaining fibrinogen weight percentages below 5% w/v and thrombin
concentrations under 20 U/ml, polymerization rates can be controlled to allow adequate time
for percutaneous delivery. The dotted line indicates the operational upper viscosity limit of
200 cP.
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(a) MSCs cultured in fibrin gels maintained excellent viability over 72 h of culture. (b) Live-
dead stain of MSCs 72 h after culture in a fibrin gel (living cells stain green, dead cells stain
red, scale bar: 500 μm). (c, d) SEM of a 2% (w/v) fibrinogen gel polymerized with 20 U/ml of
thrombin showing a heterogenous structure with pore sizes in the 20–40 μm range.
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(a) Intramyocardial delivery of MSCs suspended in fibrin glue results in gross retention of
hydrogel (b, scale bar: 10 mm) and noticeable infarct thickening (c, scale bar: 5 mm) 10 days
after infarction and injection. (d) Trichrome staining of a left ventricular cross section
demonstrates intramural presence of injectate (scale bar: 500 μm). (e) Quantification of
iridium-labeled MSCs confirms a significant increase in local cardiac retention as well as
prevention of end organ redistribution when MSCs are delivered in fibrin glue (black bars)
compared to saline (white bars).
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